Background and Purpose—The cost-effectiveness of dabigatran for stroke prevention in
patients with atrial fibrillation and prior stroke or transient ischemic attack has not been …

Background: Warfarin reduces the risk for ischemic stroke in patients with atrial fibrillation
(AF) but increases the risk for hemorrhage. Dabigatran is a fixed-dose, oral direct thrombin …

Background—Recent studies have investigated alternatives to warfarin for stroke
prophylaxis in patients with atrial fibrillation (AF), but whether these alternatives are cost …

Oral dabigatran etexilate is indicated for the prevention of stroke and systemic embolism in
patients with atrial fibrillation (AF) in whom anticoagulation is appropriate. Based on the RE …

Objective To assess the cost-effectiveness of dabigatran etexilate, a new oral anticoagulant,
versus warfarin and other alternatives for the prevention of stroke and systemic embolism in …

The RE-LY study demonstrated the safety and efficacy of dabigatran relative to warfarin for
stroke prevention in non-valvular atrial fibrillation. It is important to further evaluate safety …

Objectives: This study sought to compare the net clinical benefit of dabigatran 110 mg bid
and 150 mg bid with that of warfarin in patients with atrial fibrillation (AF). Background: In …

Background Warfarin reduces the risk of stroke in patients with atrial fibrillation but increases
the risk of hemorrhage and is difficult to use. Dabigatran is a new oral direct thrombin …

Background This register-based observational study compares dabigatran to warfarin for
secondary stroke prevention in atrial fibrillation patients among both “new starters” on …

Purpose This study aimed to evaluate the cost-effectiveness of dabigatran and rivaroxaban
compared with warfarin for the prevention of stroke in patients with atrial fibrillation (AF) in …